Trial · NCT02858310
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase I Dose Escalation | STARTED | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | 3 | |
| Phase I Dose Escalation | STARTED | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | 3 | |
| Phase I Dose Escalation | STARTED | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | 6 | |
| Phase I Dose Escalation | STARTED | Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells | 0 | |
| Phase I Dose Escalation | STARTED | Participants Enrolled But Were Not Treated | 36 | |
| Phase I Dose Escalation | COMPLETED | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | 3 | |
| Phase I Dose Escalation | COMPLETED | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | 3 | |
| Phase I Dose Escalation | COMPLETED | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | 6 | |
| Phase I Dose Escalation | COMPLETED | Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells | 0 | |
| Phase I Dose Escalation | COMPLETED | Participants Enrolled But Were Not Treated | 0 | |
| Phase I Dose Escalation | NOT COMPLETED | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | 0 | |
| Phase I Dose Escalation | NOT COMPLETED | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | 0 | |
| Phase I Dose Escalation | NOT COMPLETED | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | 0 | |
| Phase I Dose Escalation | NOT COMPLETED | Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells | 0 | |
| Phase I Dose Escalation | NOT COMPLETED | Participants Enrolled But Were Not Treated | 36 | |
| Phase II Recommended Phase 2 Dose | STARTED | Phase I:Dose Escalation Cohort; Arm 1:Phase I:DoseLevel 1: 1 x 10^9 E7 T-Cell Receptor (TCR) Cells | 0 | |
| Phase II Recommended Phase 2 Dose | STARTED | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 2: 1 x 10^10 E7 T-Cell Receptor Cells | 0 | |
| Phase II Recommended Phase 2 Dose | STARTED | Phase I: Dose Escalation Cohort; Arm 1: Phase I; Dose Level 3: 1 x 10^11 E7 Cells | 0 | |
| Phase II Recommended Phase 2 Dose | STARTED | Phase II Cohort; Arm 2: Phase II: 1 x 10^11 E7 Cells | 18 | |
| Phase II Recommended Phase 2 Dose | STARTED | Participants Enrolled But Were Not Treated | 158 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02858310/flow